MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.410
-0.160
-6.23%
After Hours: 2.410 0 0.00% 16:00 03/08 EST
OPEN
2.580
PREV CLOSE
2.570
HIGH
2.580
LOW
2.390
VOLUME
280.28K
TURNOVER
--
52 WEEK HIGH
3.639
52 WEEK LOW
1.600
MARKET CAP
134.89M
P/E (TTM)
-4.9144
1D
5D
1M
3M
1Y
5Y
Analysts Estimate Pieris Pharmaceuticals (PIRS) to Report a Decline in Earnings: What to Look Out for
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 3d ago
Anemia Drugs Market Demand Fuelled by Increased R and D Activities, Says Market.us
Mar 02, 2021 (WiredRelease via Comtex) -- A recent systematic review report on “Anemia Drugs Market is Expected to Thrive at Impressive CAGR by 2031 |...
marketresearch.biz · 6d ago
Global Anaemia Drugs Market to be Driven by Growing Prevalence of CKD Anaemia in the Forecast Period of 2021-2026
Feb 27, 2021 (AB Digital via COMTEX) -- The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses...
ABNewswire · 02/27 12:14
Pieris Pharmaceuticals Granted U.S. Patent Titled 'Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&f=G&l=50&d=PTXT&p=1&S1=pieris&OS=pieris&RS=pieris
Benzinga · 02/23 20:57
Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference
BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and ot...
ACCESSWIRE · 02/23 13:00
Chemotherapy Induced Anemia Drug Market Growth (2021-2025), Size, Industry Growth by Global Major Companies Profile, Competitive Landscape and Key Regions.
Feb 23, 2021 (The Expresswire) -- Global “Chemotherapy Induced Anemia Drug Market” (2021-2025) examines the effect of different Factors affecting the market...
The Express Wire · 02/23 09:36
Chemotherapy Induced Anemia Drug Market Size, Share, Growth 2021, Opportunities And Latest Trends By Leading Regions, And Manufacturers To 2026
Feb 22, 2021 (The Expresswire) -- Global Chemotherapy Induced Anemia Drug Market 2021 industry research report gives Advancement strategies and plans are...
The Express Wire · 02/23 04:49
Hepcidin Market Size, Share, Growth 2021 to 2026, Forecast by Manufacturers, Regions, Global Type and Application
Feb 22, 2021 (The Expresswire) -- Global Hepcidin Market 2021 industry research report gives Advancement strategies and plans are talked about just as...
The Express Wire · 02/23 04:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PIRS. Analyze the recent business situations of Pieris Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PIRS stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 38.44M
% Owned: 68.67%
Shares Outstanding: 55.97M
TypeInstitutionsShares
Increased
28
1.40M
New
24
210.09K
Decreased
20
1.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
James Geraghty
Chairman/Independent Director
james Geraghty
President/Chief Executive Officer/Director
Stephen Yoder
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Treasurer
Thomas Bures
Senior Vice President/Chief Scientific Officer
Hitto Kaufmann
Senior Vice President/General Counsel/Secretary
Ahmed Mousa
Senior Vice President
Ingmar Bruns
Senior Vice President
Eckhard Niemeier
Senior Vice President
Shane Olwill
Independent Director
Ann Barbier
Independent Director
Peter Kiener
Independent Director
Christopher Kiritsy
Independent Director
Michael Richman
Independent Director
Maya Said
Independent Director
Matthew Sherman
No Data
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.